|
業務類別
|
Biotechnology |
|
業務概覽
|
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally. |
| 公司地址
| 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477 |
| 電話號碼
| +1 832 819-3232 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.greenwichlifesciences.com |
| 員工數量
| 8 |
| Dr. Jaye Thompson, M.S.,PhD |
Vice President, Clinical and Regulatory Affairs |
-- |
15/04/2025 |
| Mr. Snehal S. Patel |
Principal Accounting Officer, Chief Executive Officer, Chief Financial Officer and Director |
美元 612.56K |
03/11/2025 |
| Dr. F Joseph. Daugherty |
Chief Medical Officer and Director |
-- |
03/11/2025 |
|
|
| Mr. David B. McWilliams |
Chairman of the Board |
03/11/2025 |
| Mr. Snehal S. Patel |
Principal Accounting Officer, Chief Executive Officer, Chief Financial Officer and Director |
03/11/2025 |
| Dr. F Joseph. Daugherty |
Chief Medical Officer and Director |
03/11/2025 |
| Mr. Eric Rothe |
Independent Director |
03/11/2025 |
| Mr. Kenneth Hallock |
Independent Director |
03/11/2025 |
|
|
|
|
